Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 50 years on the day of inclusion~* Informed consent form has been signed and dated~* Able to attend all scheduled visits and comply with all trial procedures~* Subject is healthy, as determined by medical history and physical examination~* For a woman of child-bearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to first vaccination until 4 weeks after the last vaccination.~Exclusion Criteria:~* History of anaphylactic reaction or asthma~* Unknown pregnancy or positive serum/urine pregnancy test~* Currently breastfeeding a child~* Chronic illness, that in the opinion of the investigator, is at a stage that could interfere with trial conduct or completion~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances~* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures~* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for pandemic influenza vaccination which may be received at least two weeks before the study vaccines~* Planned receipt of any vaccine in the 4 weeks following the trial vaccination, except for pandemic influenza vaccination in the event of a local or national immunization program~* Known seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C~* Laboratory confirmed/self-reported thrombocytopenia contraindicating intramuscular (IM) vaccination~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Identified as a study site employee who is involved in the protocol and may have direct access to trial-related data~* Previous vaccination against pneumococcal disease (in the previous 5 years)~* History of pneumococcal infection (confirmed either clinically, serologically, or microbiologically) within 5 years~* At high risk for pneumococcal infection during the trial~* Living in a household with children \<5 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine Formulation 1 (Low dose) (Type: EXPERIMENTAL): Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
- Vaccine Formulation 2 (Middle dose) (Type: EXPERIMENTAL): Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
- Vaccine Formulation 3 (High dose) (Type: EXPERIMENTAL): Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
- Placebo Pooled (Type: PLACEBO_COMPARATOR): Participants who receive 2 injections of tris buffered saline

Based on this trial design, predict the completion outcome and termination type (if applicable).